COVID-19NCT05614388
A Study on Voluntary Routine COVID-19 Self-testing in Mizoram, India.
A study testing COVID-19 Self testing and related messaging in people with COVID-19, run by PATH.
Trial summary
This interventional study aims to evaluate the utilization, adherence, and acceptability of voluntary, free, routine self-testing for COVID-19 (Corona Virus (19) Disease) and related information, education and communication (IEC) messages in two institutional settings in Mizoram, India. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- COVID-19
- What is being tested?
- COVID-19 Self testing and related messaging
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 646 participants
- Where
- No sites listed yet
- Study dates
- Dec 2022to May 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Above the age of 18 years, irrespective of gender and past COVID-19 status
- Registered with participating institutions
- Able and willing to provide informed consent
- Owns a smartphone capable of downloading the SURE STATUS app for uploading results
- Able to read the instructions in the Mizo or English or Hindi
Who cannot join
- Does not consent.
- Has any contraindication to nasal sample collection, including recent nasal injury, nasal surgeries.
- Personnel who are directly involved in the conduct of the study, e.g., investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log.
Trial locations and contacts
No sites are listed yet.
About this study
Official title: A Study on Utilization, Adherence, and Acceptability of Voluntary Routine COVID-19 Self-testing Among Students, Staff and Health Workers at Two Institutions in Mizoram, India.
This interventional study aims to evaluate the utilization, adherence, and acceptability of voluntary, free, routine self-testing for COVID-19 (Corona Virus (19) Disease) and related information, education and communication (IEC) messages in two institutional settings in Mizoram, India. In addition, it will assess and measure preferences for assisted vs unassisted and observed vs unobserved self-testing, assess adherence and measure dropout rate and describe dropout characteristics.
The research questions it aims to address are -
- What is the uptake and adherence of voluntary, free, routine self-testing for COVID-19 and related IEC messages vy students, employees, and healthcare workers in two institutional settings in India? Are there any dropouts from routine self-testing and what are the factors related to dropouts?
- What is the preferred mode of self-testing- observed or unobserved, assisted or unassisted? Do these preferences change over time? The researchers will be measuring - Utilization rate, Adherence rate, Proportion of preference to assisted vs unassisted self-testing, Proportion of preference to observed vs unobserved self-testing, Time to dropout and Acceptability of COVID-19 self-testing kits.
Read the detailed description
Testing is a critical component of the pandemic response. It serves two purposes; for clinical purposes, it focuses on identifying disease in symptomatic patients, while testing for epidemiological purposes, spread in the population is also assessed. India uses a mix of both Reverse Transcriptase Polymerase Chain Reaction (RT PCR) and Antigen Rapid Diagnostic Tests (Ag RDTs) for COVID-19 testing. RT PCR is the reference standard test for detection of the virus. However, not all facilities have RT PCR, and many communities have poor access. This leads to a long turn-around time (TAT) for the results to be obtained and a high load on RT PCR facilities. Hence, to prevent the spread of the virus, cases must get detected early. At the peak of the first wave of the pandemic in the country, Ag RDTs constituted close to 50% of all the tests conducted in the country. Self-testing for COVID-19 has emerged as a viable complementary testing modality. The use of self-testing kits while ensuring the availability of other COVID-19 tests at the nearest point of care addresses many of the usual barriers to uptake of services, leading to timely testing of individuals, diagnosis, and access to care. It can also reduce the burden on existing testing infrastructure especially during a surge in the cases. It also reduces overcrowding at testing facilities thereby reducing the risk of disease transmission. To improve access to testing and prevent overreliance on RT PCR laboratories, the Indian Council of Medical Research (ICMR) approved and validated the use of COVID-19 self-testing kits. As of March 2022, sixteen self-testing kits have been validated in India of which 10 are found to be satisfactory. While there are many benefits to self-testing, it is also essential to understand the utilization of the self-testing strategy, including whether or not the community can follow the steps for self-testing and what support, if any, the community may require to use self-test kits.
The present study proposes the demonstration of ICMR and US-FDA (United States Food \& Drug Administration) approved SURE STATUS self-testing kit in the healthcare workers and educational institution setting in Mizoram for a period of 5 months. With the ease of lockdown and movement restrictions, workplaces and educational institutes are gradually opening up. However, with the threat of the pandemic still looming large, it is prudent to put in place systems for regular screening within these settings to promote early diagnosis and care and prevent outbreaks. COVID-19 self-test has been identified as one way any institution can scale up COVID-19 testing to improve COVID-19 status awareness by reaching out to as many people as possible at a given point of time.
While COVID-19 self-tests are available and widely used in India, these kits are largely used within the confines of individual homes. It is learnt that the reporting of the results of the self-test is poor as compared to the utilization of the self-test kits. To the investigator's knowledge, no study has been conducted in India to assess the utilization of self-testing as a routine procedure in places of mass indoor gathering, like workplaces and educational institutions. To address this gap, the investigators will conduct a study to evaluate the utilization, adherence, and acceptability of routine COVID-19 self-testing among students, employees and healthcare workers in two congregate settings: one University College and one Medical College and Hospital in Mizoram, India. The proposed study will document challenges, if any, in reporting of self-test results and document the key processes in operationalizing routine COVID-19 self-testing among students, employees and healthcare workers and provide learning and recommendations for systematic use of self-tests for future models of institution based COVID-19 self-testing in congregate settings.
- Conditions
- COVID-19
- Being tested
- COVID-19 Self testing and related messaging
- Keywords
- COVID 19, Self-Test, Pandemic Preparedness, Infectious diseases
- Medical subject headings
- COVID-19, Communicable Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
COVID-19 Self testing and related messagingDiagnostic test
Provisioning of voluntary, free self-testing for COVID-19 (approved and validated in the country) and related Information, Education and Communication (IEC) messages
| Study group | Role | What they receive |
|---|---|---|
| Study participants | Experimental | The study procedure is universal to all the participants from both the institutes. There are no control arms defined separately. The groups within the participants include - include health care workers, non-medical hospital staff and medical students at ZMC; and faculty, students and supporting staff at the Pacchunga University College. Receives: Diagnostic Test: COVID-19 Self testing and related messaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
Utilization rate
Individual level: the proportion of tests each individual uses till the end of the follow-up period from the minimum number of tests allocated to them.
Sample-level: mean and standard deviations calculated based on the individual utilisation rates
Measured: 5 Months
Adherence Rate
Individual level: the proportion of tests an individual performs according to the testing schedule over the total number of tests they perform.
Sample-level: mean and standard deviations calculated based on the individual adherence rates
Measured: 5 Months
Preferences of participants on self testing
Proportion of preference to assisted vs unassisted self-testing
Measured: 5 Months
Observation proportions of participants on self testing
Proportion of preference to observed vs unobserved self-testing
Measured: 5 Months
Time to dropout
The time to drop out will be the time from enrolment of the participant till drop-out
Measured: 5 Months
Acceptability of COVID-19 self-testing kits
A composite indicator based on ease of use of COVID-19 self-testing kits, ease of interpretation of test results, and recommendation to others
Measured: 5 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2022
- Study startDec 2022 (estimated)
- Primary completionApr 2023 (estimated)
- Study completionMay 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- The participants include health care workers, non-medical hospital staff and medical students at ZMC; and faculty, students and supporting staff at the Pacchunga University College. All these groups will be participating in the study simultaneously. The study results will be compared for all these 6 groups.
- Masking
- None (open label)
- Enrolment
- 646 participants (estimated)
Sponsor and investigators
- Lead sponsor
- PATH
- Sponsor type
- University, hospital or other
- Collaborators
- UNITAID, Zoram Medical College (ZMC), Pacchunga University College, Association for Leprosy Education Rehabilitation & Treatment India (ALERT India), Government of Mizoram
- Responsible party
- Sponsor
- Investigators
- Jane Ralte, MD, Principal investigator, Zoram Medical College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05614388
- Sponsor's protocol ID
- RES-376
- Status last verified
- Nov 2022
- First submitted
- 9 Nov 2022
- Last updated
- 21 Nov 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We do not plan to share any individual participant data. We will share collective learnings on various parameters at both the sites.
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study on Utilization, Adherence, and Acceptability of Voluntary Routine COVID-19 Self-testing Among Students, Staff and Health Workers at Two Institutions in Mizoram, India.
- ClinicalTrials.gov ID
- NCT05614388
- Acronym / sponsor ID
- RES-376
- Conditions
- COVID-19
- Keywords
- COVID 19, Self-Test, Pandemic Preparedness, Infectious diseases
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 646 participants (estimated)
- Lead sponsor
- PATHUniversity, hospital or other
- Collaborators
- UNITAID, Zoram Medical College (ZMC), Pacchunga University College, Association for Leprosy Education Rehabilitation & Treatment India (ALERT India), Government of Mizoram
- Study start
- Dec 2022 (estimated)
- Primary completion
- Apr 2023 (estimated)
- Study completion
- May 2023 (estimated)
- First posted
- 14 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This interventional study aims to evaluate the utilization, adherence, and acceptability of voluntary, free, routine self-testing for COVID-19 (Corona Virus (19) Disease) and related information, education and communication (IEC) messages in two institutional settings in Mizoram, India. In addition, it will assess and measure preferences for assisted vs unassisted and observed vs unobserved self-testing, assess adherence and measure dropout rate and describe dropout characteristics.
The research questions it aims to address are -
- What is the uptake and adherence of voluntary, free, routine self-testing for COVID-19 and related IEC messages vy students, employees, and healthcare workers in two institutional settings in India? Are there any dropouts from routine self-testing and what are the factors related to dropouts?
- What is the preferred mode of self-testing- observed or unobserved, assisted or unassisted? Do these preferences change over time? The researchers will be measuring - Utilization rate, Adherence rate, Proportion of preference to assisted vs unassisted self-testing, Proportion of preference to observed vs unobserved self-testing, Time to dropout and Acceptability of COVID-19 self-testing kits.
Detailed description
Testing is a critical component of the pandemic response. It serves two purposes; for clinical purposes, it focuses on identifying disease in symptomatic patients, while testing for epidemiological purposes, spread in the population is also assessed. India uses a mix of both Reverse Transcriptase Polymerase Chain Reaction (RT PCR) and Antigen Rapid Diagnostic Tests (Ag RDTs) for COVID-19 testing. RT PCR is the reference standard test for detection of the virus. However, not all facilities have RT PCR, and many communities have poor access. This leads to a long turn-around time (TAT) for the results to be obtained and a high load on RT PCR facilities. Hence, to prevent the spread of the virus, cases must get detected early. At the peak of the first wave of the pandemic in the country, Ag RDTs constituted close to 50% of all the tests conducted in the country. Self-testing for COVID-19 has emerged as a viable complementary testing modality. The use of self-testing kits while ensuring the availability of other COVID-19 tests at the nearest point of care addresses many of the usual barriers to uptake of services, leading to timely testing of individuals, diagnosis, and access to care. It can also reduce the burden on existing testing infrastructure especially during a surge in the cases. It also reduces overcrowding at testing facilities thereby reducing the risk of disease transmission. To improve access to testing and prevent overreliance on RT PCR laboratories, the Indian Council of Medical Research (ICMR) approved and validated the use of COVID-19 self-testing kits. As of March 2022, sixteen self-testing kits have been validated in India of which 10 are found to be satisfactory. While there are many benefits to self-testing, it is also essential to understand the utilization of the self-testing strategy, including whether or not the community can follow the steps for self-testing and what support, if any, the community may require to use self-test kits.
The present study proposes the demonstration of ICMR and US-FDA (United States Food \& Drug Administration) approved SURE STATUS self-testing kit in the healthcare workers and educational institution setting in Mizoram for a period of 5 months. With the ease of lockdown and movement restrictions, workplaces and educational institutes are gradually opening up. However, with the threat of the pandemic still looming large, it is prudent to put in place systems for regular screening within these settings to promote early diagnosis and care and prevent outbreaks. COVID-19 self-test has been identified as one way any institution can scale up COVID-19 testing to improve COVID-19 status awareness by reaching out to as many people as possible at a given point of time.
While COVID-19 self-tests are available and widely used in India, these kits are largely used within the confines of individual homes. It is learnt that the reporting of the results of the self-test is poor as compared to the utilization of the self-test kits. To the investigator's knowledge, no study has been conducted in India to assess the utilization of self-testing as a routine procedure in places of mass indoor gathering, like workplaces and educational institutions. To address this gap, the investigators will conduct a study to evaluate the utilization, adherence, and acceptability of routine COVID-19 self-testing among students, employees and healthcare workers in two congregate settings: one University College and one Medical College and Hospital in Mizoram, India. The proposed study will document challenges, if any, in reporting of self-test results and document the key processes in operationalizing routine COVID-19 self-testing among students, employees and healthcare workers and provide learning and recommendations for systematic use of self-tests for future models of institution based COVID-19 self-testing in congregate settings.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- The participants include health care workers, non-medical hospital staff and medical students at ZMC; and faculty, students and supporting staff at the Pacchunga University College. All these groups will be participating in the study simultaneously. The study results will be compared for all these 6 groups.
| Arm | Type | Receives |
|---|---|---|
| Study participants | Experimental | Diagnostic Test: COVID-19 Self testing and related messagingThe study procedure is universal to all the participants from both the institutes. There are no control arms defined separately. The groups within the participants include - include health care workers, non-medical hospital staff and medical students at ZMC; and faculty, students and supporting staff at the Pacchunga University College. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Above the age of 18 years, irrespective of gender and past COVID-19 status
- Registered with participating institutions
- Able and willing to provide informed consent
- Owns a smartphone capable of downloading the SURE STATUS app for uploading results
- Able to read the instructions in the Mizo or English or Hindi
Key exclusion criteria (3 listed)
- Does not consent.
- Has any contraindication to nasal sample collection, including recent nasal injury, nasal surgeries.
- Personnel who are directly involved in the conduct of the study, e.g., investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| COVID-19 Self testing and related messagingProvisioning of voluntary, free self-testing for COVID-19 (approved and validated in the country) and related Information, Education and Communication (IEC) messages | Diagnostic test | Study participants |
Primary outcome
Utilization rate
Time frame: 5 Months
Individual level: the proportion of tests each individual uses till the end of the follow-up period from the minimum number of tests allocated to them. Sample-level: mean and standard deviations calculated based on the individual utilisation rates
Adherence Rate
Time frame: 5 Months
Individual level: the proportion of tests an individual performs according to the testing schedule over the total number of tests they perform. Sample-level: mean and standard deviations calculated based on the individual adherence rates
Preferences of participants on self testing
Time frame: 5 Months
Proportion of preference to assisted vs unassisted self-testing
Observation proportions of participants on self testing
Time frame: 5 Months
Proportion of preference to observed vs unobserved self-testing
Time to dropout
Time frame: 5 Months
The time to drop out will be the time from enrolment of the participant till drop-out
Acceptability of COVID-19 self-testing kits
Time frame: 5 Months
A composite indicator based on ease of use of COVID-19 self-testing kits, ease of interpretation of test results, and recommendation to others
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2022.
- Individual participant dataSharing planned: No. We do not plan to share any individual participant data. We will share collective learnings on various parameters at both the sites.
Related trials for COVID-19
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
RecruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruitingObservational study
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jane Ralte, MD principal investigator
Zoram Medical College
Questions about this trial
What is this clinical trial studying?
A study testing COVID-19 Self testing and related messaging in people with COVID-19, run by PATH.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Muneer Kutty, MPH (+919999798283, mkutty@path.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Utilization rate (time frame: 5 Months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2022.